PCN8 OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS  by Goulart, BHL et al.
248 Abstracts
(NSCLC). Using data from the SEER-Medicare cancer registry,
we examined trends in use, outcomes, and costs of care for
NSCLC patients receiving chemotherapy in community settings
from 1994–2001. METHODS: Patients were included if they
were diagnosed with locally advanced or metastatic (TNM stages
IIIb and IV) NSCLC between 1 January 1994 and 31 December
2001. Patients were stratiﬁed based on initial chemotherapy
agent(s) used. Cox proportional hazards models were used to
compare survival as a function of initial chemotherapy regimen,
controlling for age, sex, race, noncancer comorbidity, stage at
diagnosis, SEER region, and receipt of cancer-related surgery or
radiation therapy in the ﬁrst 3 months following diagnosis. Life-
time medical costs were calculated for each chemotherapy group
using the Kaplan Meier sample average estimator. RESULTS: A
total of 14,875 met inclusion criteria, 7411 (49.8%) stage IIIb
and 7464 (50.2%) stage VI at diagnosis. Chemotherapy use in
the ﬁrst 3 months following diagnosis increased from 21% to
43% of those diagnosed over the observation period (p < 0.01).
Persons > = 75 (OR = 0.91), females (OR = 0.87), African Amer-
icans (OR = 0.49) and those with >1 comorbidity (OR = 0.84)
were signiﬁcantly less likely to receive chemotherapy. Multivari-
ate Cox proportional hazards models demonstrated that survival
was inferior for those not receiving a platinum agent (p < 0.01).
Lifetime medical care costs differed signiﬁcantly among regimens
[mean (std. dev.)]: no chemotherapy $27,833 (372); cisplatin or
carboplatin alone $128,179 (11,968); cisplatin or carboplatin
plus taxane $78,451 (2,898); cisplatin/carboplatin + other agent
not taxane $68,173 (2663) single agent or doublet excluding 
cisplatin or carboplatin $55,959 (2331). CONCLUSIONS:
Chemotherapy use for advanced NSCLC has increased substan-
tially. Platinum containing regimens (recommended by guide-
lines) are superior. Some combinations are more costly but do
not offer improved survival.
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OBJECTIVES: Targeted therapies, functional imaging and trans-
lational research have enabled utilization of a new endpoint in
phase I oncology trials, known as Surrogate Endpoints (SEs) or
biomarkers. Investigators hope that SEs will improve the efﬁ-
ciency of drug-development. However, whether SEs can substi-
tute for traditional endpoints is unknown. The role of SEs in
drug selection, target validation, dosing and schedule is not
deﬁned. METHODS: We analyzed phase I single-agent abstracts
in PASCO from 1992 to 2002 that included at least one SE. Sub-
sequent publications were analyzed based on the primary SE.
Drugs were classiﬁed as cytotoxic, biologic, or targeted and SEs
classiﬁed by their technology (imaging, blood biomarkers or
advanced histology). We designed 4 questions to evaluate the
role of SEs, beginning with: “Did the SE help . . . : 1) “. . . deter-
mine the dose for phase II?”; 2) “. . . in ﬁnding the schedule?”;
3) “. . . with the author’s conclusions?”; and 4) “. . . validate that
the target was affected?”. McNemar’s and chi-square tests com-
pared the utility of SEs across these questions and across drug
classes, respectively. We also related the budgets of 18 institu-
tional trials to their number of SEs. RESULTS: Of 74 trials, 57%
tested biologics, 24% small molecules, 14% cytotoxic and 5%
other. According to technology: 68% were blood studies, 24%
histologic analysis, and 7% imaging. The frequency of “yes” for
the 4 questions was 15%, 16%, 38%, and 62%, respectively (p
< 0.001 between questions), without differences between classes.
The budgeted cost of adding a SE was US$6675 per patient.
CONCLUSIONS: SEs modestly aided in deﬁning dose and
schedule for future studies and in the overall drug-development
process. They helped in validating that the therapy affected the
intended target. Better preclinical evaluation of SEs may enhance
their utility. Further research should help deﬁne how best to
incorporate SEs into trial design.
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OBJECTIVES: Prostate Cancer patients using Androgen Depri-
vation Therapy (ADT) are considered at a higher risk for osteo-
porotic fractures due to excessive loss of bone mineral density
(BMD). This study measured the incremental Cost Effectiveness
(CE) of adding bisphosphonates to ADT based on QALYs
gained. METHODS: A Markov model of fracture-risk associated
with osteoporosis in patients with non-metastatic prostate cancer
was developed to compare the incremental CE of adding
pamidronate or zoledronic acid to ADT. Literature-based esti-
mates of costs of treating osteoporotic fractures and average
wholesale prices of bisphosphonates were used. Disutilities pub-
lished by the National Osteoporotic Foundation for the ﬁrst and
subsequent year following an osteoporotic fracture were used to
measure effectiveness of prescribing bisphosphonates. Robust-
ness of assumptions was tested using deterministic and stochas-
tic sensitivity analyses. RESULTS: The Markov analyses yielded
total incremental cost of $17,009.40 for ADT + pamidronate
and of $25,838.90 for ADT + zoledronic acid over ADT only
option. Adding pamidronate resulted in a gain of 0.0128 QALYs
at a marginal CE of $1,327,746 as compared to zoledronic acid
which resulted in a gain of 0.015 QALYs at a marginal CE of
$1,722,593. Monte Carlo simulation as well as one-way and
two-way sensitivity analyses indicated robustness of the key
assumptions such as probability of fracture, probability of death
due to hip fracture and discount rate. CONCLUSIONS: In case
of reducing the fracture-risk in non-metastatic prostate cancer
patients using bisphosphonates resulted in nominal gain in
QALYs at a very high marginal CEs for both drugs.
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OBJECTIVES: Basal cell carcinoma (BCC) is a common malig-
nant tumour, usually treated with surgery though the cosmetic
appearance of the treated lesions can be poor. Methyl aminole-
vulinate cream is the ﬁrst topical PDT therapy licensed in the UK
for superﬁcial, or mid-face, large or recurrent nodular BCC and
can be considered for lesions unsuitable for surgery. The aim of
this evaluation was to assess the cost-effectiveness of MAL-PDT
versus excision. METHODS: Clinical outcomes were from a
comparative trial of nodular BCC. The clinical response for
MAL-PDT from a non-comparative trial of primary superﬁcial
BCC (Horn et al, in press) was also used to reﬂect the subgroup
most likely to be treated with MAL-PDT. Lesion reoccurrence
was derived from published literature and an expert Delphi panel
provided resource use. The NHS perspective was taken and only
direct costs were considered. Decision analysis was used with
MAL-PDT or excision as ﬁrst line therapy and, if no lesion
